Tarek Jebrini

Dr. Tarek Jebrini

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2024 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Open access
PDF file
TJTarek Jebrini
Tarek Jebrini
ATAnabel Thomas
Anabel Thomas
SSSimone Sachenbacher
Simone Sachenbacher
FHFides Heimkes
Fides Heimkes
SKSusanne Karch
Susanne Karch
KAKristina Adorjan
Kristina Adorjan
Cognitive complaints are common signs of the Post COVID-19 (PC) condition, but the extent and type of cognitive impairment may be heterogeneous. Little is known about neuropsychological treatment options. Preliminary evidence suggests cognitive symptoms may improve with cognitive training and naturally over time. In this clinical trial, we examined whether participation in a weekly group consisting of cognitive training and group psychotherapy is feasible and would exert beneficial effects on cognitive performance in PC and whether improvements were associated with intervention group participation or represented a temporal improvement effect during syndrome progression. 15 PC patients underwent an 8-week intervention. Cognitive performance was assessed before and after each intervention group participation. A control group of 15 PC patients with subjective neurocognitive or psychiatric complaints underwent two cognitive assessments with comparable time intervals without group participation. To attribute changes to the intervention group participation, interaction effects of group participation and time were checked for significance. This is an exploratory, non-randomized, non-blinded controlled clinical trial. Within the intervention group, significant improvements were found for most cognitive measures. However, significant time x group interactions were only detected in some dimensions of verbal memory and visuo-spatial construction skills. Significant time effects were observed for attention, concentration, memory, executive functions, and processing speed. The intervention setting was feasible and rated as helpful and relevant by the patients. Our results suggest that cognitive symptoms of PC patients may improve over time. Patients affected by both neurocognitive impairments and mental disorders benefit from group psychotherapy and neurocognitive training. The present study provides evidence for a better understanding of the dynamic symptomatology of PC and might help to develop further studies addressing possible therapy designs. The main limitations of this exploratory feasibility trial are the small sample size as well as the non-randomized design due to the clinical setting.

16 January 2025 in Infection
Verified
Journal Article
Open access
PDF file
TJTarek Jebrini
Tarek Jebrini
MRMichael Ruzicka
Michael Ruzicka
FVFelix Völk
Felix Völk
GFGerardo Jesus Ibarra Fonseca
Gerardo Jesus Ibarra Fonseca
APAnna Pernpruner
Anna Pernpruner
HSHans Christian Stubbe
Hans Christian Stubbe
The Post COVID-19 condition (PCC) is a complex disease affecting health and everyday functioning. This is well reflected by a patient’s inability to work (ITW). In this study, we aimed to investigate factors associated with ITW (1) and to design a machine learning-based model for predicting ITW (2) twelve months after baseline. We selected patients from the post COVID care study (PCC-study) with data on their ability to work. To identify factors associated with ITW, we compared PCC patients with and without ITW. For constructing a predictive model, we selected nine clinical parameters: hospitalization during the acute SARS-CoV-2 infection, WHO severity of acute infection, presence of somatic comorbidities, presence of psychiatric comorbidities, age, height, weight, Karnofsky index, and symptoms. The model was trained to predict ITW twelve months after baseline using TensorFlow Decision Forests. Its performance was investigated using cross-validation and an independent testing dataset. In total, 259 PCC patients were included in this analysis. We observed that ITW was associated with dyslipidemia, worse patient reported outcomes (FSS, WHOQOL-BREF, PHQ-9), a higher rate of preexisting psychiatric conditions, and a more extensive medical work-up. The predictive model exhibited a mean AUC of 0.83 (95% CI: 0.78; 0.88) in the 10-fold cross-validation. In the testing dataset, the AUC was 0.76 (95% CI: 0.58; 0.93). In conclusion, we identified several factors associated with ITW. The predictive model performed very well. It could guide management decisions and help setting mid- to long-term treatment goals by aiding the identification of patients at risk of extended ITW.

1 May 2021
Verified
Journal Article
Closed access
TJTarek Jebrini
Tarek Jebrini
MRMatthias A Reinhard
Matthias A Reinhard
MOMoritz Ortmann
Moritz Ortmann
MSMichael Strupf
Michael Strupf
MRMike Rüb
Mike Rüb
KAKristina Adorjan
Kristina Adorjan

24 January 2025 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Open access
PDF file
TJTarek Jebrini
Tarek Jebrini
HSHans Christian Stubbe
Hans Christian Stubbe
MRMichael Ruzicka
Michael Ruzicka
KAKristina Adorjan
Kristina Adorjan

Verified
Journal Article
Open access
PDF file
TJTarek Jebrini
Tarek Jebrini
MRMichael Ruzicka
Michael Ruzicka
HSHans Christian Stubbe
Hans Christian Stubbe
KAKristina Adorjan
Kristina Adorjan
Despite the increasing evidence of neurocognitive impairment (NCI) in patients suffering from post-COVID-19 conditions (PCC), the interplay between patient-reported symptoms and objective findings remains poorly characterized. Valid diagnostic tests and sufficient treatment strategies are lacking. We conducted a narrative perspective synthesis of current findings of NCI, standardized assessments (e.g., MoCA, PCCIS), and their association with inflammatory parameters. We highlighted findings on the discrepancy of subjective versus objectively measured neurocognitive impairment. The “subjectivity-objectivity-gap” may contribute to patient stigmatization, impair therapy adherence and be associated with a suboptimal clinical outcome. Although established multimodal interventions, such as cognitive rehabilitation, psychoeducation, group therapy, and pharmacotherapy—show preliminary efficacy, adherence may be compromised when subjective experiences of NCI are invalidated. We summarized the current state of the literature regarding demographic and clinical risk factors such as advanced age, lower education, neuropsychiatric comorbidities and evidence on the possible underlying role of persistent neuroinflammation in NCI in PCC. This perspective emphasizes the need for evidence-based diagnostic algorithms that integrate both subjective and objective NCI, explicitly addressing the risk of stigmatization. Future research should focus on addressing the neurobiological basis of NCI, discrepant NCI findings and associated stigmatization, and incorporate these findings in clinical guidelines.

16 December 2025 in PsyArXiv
Verified
Preprint
Open access
RGRichard Gaus
Richard Gaus
FGFelix Gross
Felix Gross
MKMaxim Korman
Maxim Korman
FKFiona Klaassen
Fiona Klaassen
SMSimona Maspero
Simona Maspero
JEJohannes Eichstaedt
Johannes Eichstaedt
Millions are using generative large language models (LLMs) for mental health support in a de-facto, unregulated public health intervention, and many LLM applications are being developed to support mental health. Amid reports of both therapeutic benefit and harm, the scientific evidence supporting these applications remains inconclusive.Following PRISMA-ScR guidelines, we conducted a scoping review of PubMed, Web of Science, ACM Digital Library, IEEE Xplore, and Google Scholar from June 2017 to July 2025. We included peer-reviewed, empirical studies of transformer-based LLMs used to deliver, augment, or analyze mental health support. We extracted data on sample composition, study design, the adoption of responsible evaluation practices, and model and dataset choices.We identified 132 studies. Of 36 client-facing studies with human participants, most were small (median n = 42), uncontrolled (26/36), and recruited participants without a diagnosed mental disorder (35/36) using user experience metrics (23/36) rather than clinical outcomes (12/36). Responsible evaluation practices were generally not implemented, including safety protocols for risk detection (18%) and potentially harmful content (16%); real-world implementation was rarely addressed (7%). Across the two highest-quality controlled clinical studies, effect sizes ranged from d = .44 to .90 in symptom reduction.This gap between widespread public adoption and the limited evidence base stresses the need for robust methodological standards, including rigorous clinical trials, a focus on safety and implementation, and standardized, clinically meaningful benchmarks. Stronger evidence is needed to document that generative AI systems can safely and meaningfully improve access to mental health treatment.